Months after the annual congress of our disease (Limb-girdle Muscular Dystrophy 1F/D2), we have been able to meet and moderate, virtually, the meeting between all the research groups involved. As always, it is exciting to see first-hand the advances and the joint work between the different institutes and laboratories and how, in addition to balance, the following lines of work and research are firmly established. In addition, without giving up the effort to resume the face-to-face congress, the virtual meetings every few months are a great tool to be able to work more quickly and effectively towards the goal of new treatments.
Among other things, we were able to learn about the first results after having an antibody of our mutation available to researchers, the next steps before being able to test the various drugs in humans, the path of gene editing as a future treatment route and verify how some of the theories that the researchers handled about the behavior and causes of the disease, are finding common paths and confirmations.
As we always remember, there is work ahead and our task is hard and complicated, but we will continue to work hard so that, hopefully soon, there will be a cure for many. We are proud to have brought together world-class researchers and are very grateful for all their work and generosity.